

Date: 19 October 2026

Ref. No.: TCPCL/SEC/2026-27/00054

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2026.

The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 19 October 2026.

Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

The Meeting commenced at 11:30 A.M. and concluded at 03:45 P.M.

Kindly take above intimation on your record and oblige.

Thanking you,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

ISHWAR

RAMANBHAI

NAYI

Digitally signed by
ISHWAR RAMANBHAI
NAYI
Date: 2026.10.19
15:48:12 +05'30'

Ishwar Nayi

Company Secretary and Compliance Officer

M. No.: A37444

Encl.: As above

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE CONSOLIDATED STATEMENT OF FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Consolidated Statement of Financial Results of Tatva Chintan Pharma Chem Limited ("Holding Company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2026 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
 - a) Tatva Chintan Pharma Chem Limited – the Holding Company
 - b) Tatva Chintan USA Inc. – Wholly Owned Subsidiary
 - c) Tatva Chintan Europe B.V. – Wholly Owned Subsidiary



6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant.



CA Basant Chandak

Partner

Membership No.: 434585

UDIN No.: 26434585QMVVAA6682

Date: October 19, 2026

Place: Vadodara



Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Financial Results

for the quarter and half year ended 30 September 2026

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
	Income						
1	Revenue from operations	2,173.20	1,670.55	1,235.16	3,843.75	2,403.80	5,058.58
2	Other income	17.54	27.80	10.08	45.34	21.63	35.49
3	Total income (1+2)	2,190.74	1,698.35	1,245.24	3,889.09	2,425.43	5,094.07
	Expenses						
	Cost of materials consumed	1,140.50	1,054.07	619.87	2,194.57	1,258.76	2,627.50
	Purchases of stock-in-trade	20.43	14.03	12.38	34.46	25.27	64.94
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(98.41)	(315.19)	(83.63)	(413.60)	(151.95)	(447.05)
	Employee benefits expense	182.29	167.36	149.47	349.65	290.33	629.32
	Finance costs	27.09	20.81	5.07	47.90	9.20	28.51
	Depreciation and amortisation expenses	107.94	105.66	90.53	213.60	180.24	368.47
	Other expenses	521.50	427.32	314.92	948.82	585.94	1,252.29
4	Total expenses	1,901.34	1,474.06	1,108.61	3,375.40	2,197.79	4,523.98
5	Profit/(loss) before exceptional items and tax (3-4)	289.40	224.29	136.63	513.69	227.64	570.09
6	Exceptional items	-	13.18	-	13.18	-	-
7	Profit/(loss) before tax (5-6)	289.40	211.11	136.63	500.51	227.64	570.09
	Tax expenses/(benefits)						
	Current tax	44.39	10.10	24.80	54.49	43.42	119.68
	Deferred tax	30.50	41.20	12.66	71.70	18.54	29.87
8	Total tax expenses/(benefits)	74.89	51.30	37.46	126.19	61.96	149.55
9	Profit for the period/year (7-8)	214.51	159.81	99.17	374.32	165.68	420.54
	Other comprehensive income/(expense)						
	Items that will not be reclassified to profit or loss	0.62	0.61	(0.98)	1.23	(1.96)	2.45
	Income tax relating to items that will not be reclassified to profit or loss	(0.16)	(0.15)	0.29	(0.31)	0.57	(0.71)
	Items that will be reclassified to profit or loss	4.11	(3.65)	7.94	0.46	14.74	30.46
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
10	Other comprehensive income/(expense) for the period/year, net of tax	4.57	(3.19)	7.25	1.38	13.35	32.20
11	Total comprehensive income for the period/year (9+10)	219.08	156.62	106.42	375.70	179.03	452.74
12	Profit for the period/year attributable to:						
	- Owners of the parent	214.51	159.81	99.17	374.32	165.68	420.54
	- Non controlling interests	-	-	-	-	-	-
		214.51	159.81	99.17	374.32	165.68	420.54
13	Other comprehensive income/(expense) for the period/year attributable to:						
	- Owners of the parent	4.57	(3.19)	7.25	1.38	13.35	32.20
	- Non controlling interests	-	-	-	-	-	-
		4.57	(3.19)	7.25	1.38	13.35	32.20
14	Total comprehensive income for the period/year attributable to:						
	- Owners of the parent	219.08	156.62	106.42	375.70	179.03	452.74
	- Non controlling interests	-	-	-	-	-	-
		219.08	156.62	106.42	375.70	179.03	452.74
15	Earnings per share (Face value of Rs 10/- each) (not annualised)						
	- Basic	9.17	6.83	4.24	16.00	7.08	17.98
	- Diluted	9.17	6.83	4.24	16.00	7.08	17.98
16	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92	233.92	233.92
17	Other equity excluding revaluation reserve						7,583.67

Notes forming part of the consolidated statement of financial results

1-7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no. : +91 75748 48533

Consolidated Statement of Assets and Liabilities

as at 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	31.03.2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	5,589.61	5,741.83
Right-of-use assets	298.35	299.64
Capital work-in-progress	428.27	233.48
Other intangible assets	52.17	52.56
Intangible assets under development	13.29	15.70
Financial assets		
i) Investments	40.00	40.00
ii) Other financial assets	46.12	49.52
Deferred tax assets (net)	19.21	95.67
Other non-current assets	12.00	13.42
Total non-current assets	6,499.02	6,541.82
Current assets		
Inventories	2,489.10	1,960.74
Financial assets		
i) Trade receivables	1,783.77	1,190.31
ii) Cash and cash equivalents	106.79	57.64
iii) Bank balances other than cash and cash equivalents	45.26	30.27
iv) Loans	2.50	2.65
v) Other financial assets	1.44	3.55
Current tax assets (net)	23.00	10.53
Other current assets	236.42	239.43
Total current assets	4,688.28	3,495.12
Total assets	11,187.30	10,036.94
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,912.59	7,583.67
Equity attributable to owners	8,146.51	7,817.59
Non-controlling interests	-	-
Total equity	8,146.51	7,817.59
Liabilities		
Non-current liabilities		
Financial liabilities		
i) Borrowings	44.65	50.10
Employee benefit obligations	29.80	25.89
Other non-current liabilities	11.06	12.01
Total non-current liabilities	85.51	88.00
Current liabilities		
Financial liabilities		
i) Borrowings	1,655.30	1,153.63
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	196.31	174.77
(b) total outstanding dues of creditors other than above	658.93	407.69
iii) Other financial liabilities	92.81	126.75
Other current liabilities	324.27	259.79
Provisions	6.39	5.55
Current tax liabilities (net)	21.27	3.17
Total current liabilities	2,955.28	2,131.35
Total equity and liabilities	11,187.30	10,036.94

Notes forming part of the consolidated financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the half year ended 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
A. Cash flows from operating activities:			
Profit before tax (i)	500.51	227.64	570.09
Adjustments to reconcile profit:			
Finance costs	47.90	9.20	28.51
Depreciation and amortisation expenses	213.60	180.24	368.47
Unrealised foreign exchange loss/(gain) (net)	(39.06)	4.26	20.25
Interest income	(1.10)	(1.27)	(7.13)
Net gain on sale of current investments	-	(0.06)	(0.06)
Other non-cash items	12.82	14.91	30.80
Total adjustments to reconcile profit (ii)	234.16	207.28	440.84
Operating profit before working capital changes (iii) = (i) + (ii)	734.67	434.92	1,010.93
Changes in working capital:			
(Increase)/decrease in inventories	(528.36)	(120.83)	(621.20)
(Increase)/decrease in trade receivables	(639.29)	(153.98)	(215.03)
Decrease/(increase) in other non-current financial assets	(0.35)	0.70	(2.95)
Decrease/(increase) in other current financial assets	57.58	4.27	6.33
Decrease/(increase) in other non-current assets	1.42	2.09	(2.30)
Decrease/(increase) in other current assets	(24.54)	1.28	(35.11)
Increase/(decrease) in trade payables	331.94	43.79	196.95
(Decrease)/increase in other current financial liabilities	(19.71)	(3.59)	(2.72)
(Decrease)/increase in other current liabilities	89.26	(17.33)	43.57
(Decrease)/increase in non-current provisions	3.91	-	11.90
(Decrease)/increase in current provisions	0.84	0.42	1.31
Total changes in working capital (iv)	(727.30)	(243.18)	(619.25)
Cash generated from/(used in) operating activities (v) = (iii) + (iv)	7.37	191.74	391.68
Less: Taxes paid (Net of refund)	(44.13)	(57.93)	(76.79)
Net cash generated from/(used in) operating activities (A) = (v) + (vi)	(36.76)	133.81	314.89
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)	(308.45)	(559.99)	(1,137.74)
Government grant received for capital asset	-	-	14.20
Proceeds from sale of property, plant and equipment	2.76	0.03	3.58
(Increase)/decrease in deposits with banks	(11.23)	(19.13)	(6.80)
Purchase of Investment (Non current)	-	-	(40.00)
Purchase of current investment	-	(40.00)	(40.00)
Proceeds from sale of current investments	-	40.06	40.06
Interest income	3.56	1.27	8.28
Cash (used in) investing activities (B)	(313.36)	(577.76)	(1,158.42)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the half year ended 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
C. Cash flows from financing activities:			
Dividend paid	(46.78)	-	(23.39)
Proceeds from long-term borrowings	-	-	60.40
Repayment of long-term borrowings	(5.05)	(4.43)	(6.38)
Net proceeds from short-term borrowings	501.27	470.68	785.84
Decrease / (increase) in loans to employees	0.15	0.27	(0.28)
Interest paid	(49.95)	(9.20)	(26.87)
Cash generated from financing activities (C)	399.64	457.32	789.32
Net decrease in cash and cash equivalents D=(A+B+C)	49.52	13.37	(54.21)
Cash and cash equivalents at the beginning of the year (E)	57.64	113.74	113.74
Effect of exchange rate changes on cash and cash equivalents (F)	(0.37)	(1.73)	(1.89)
Cash and cash equivalents at the end of the year (D+E+F)	106.79	125.38	57.64
Components of cash and cash equivalents:			
Cash on hand	0.83	0.87	0.82
Balances with banks:			
- in current accounts	2.80	0.63	8.02
- in current accounts (foreign currency)	50.95	33.66	42.26
- in cash credit accounts (surplus)	-	-	0.01
- in EEFC current accounts	43.76	85.40	1.61
- in deposits with original maturity of less than 3 months	8.45	4.82	4.92
Balance as per statement of cash flows	106.79	125.38	57.64

Notes forming part of the consolidated statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Consolidated Statement of Financial Results

for the quarter and half year ended 30 September 2026

(Currency: Indian Rupees in million)


- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Consolidated Financial Results for the quarter and half year ended 30 September 2026 ("Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group" or "the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 19 October 2026.
- 2 The Consolidated Financial Results of the Company for the quarter and half year ended 30 September 2026 has been subjected to limited review by the statutory auditors of the Company, who has expressed an unmodified opinion.
- 3 The Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.

- 5 Key numbers of Standalone Statement of Financial Results for the quarter and half year ended 30 September 2026:

Sr. no.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
1.	Total income from operations (Net)	2,074.84	1,467.02	1,158.63	3,541.86	2,250.43	4,962.96
2.	Net profit/(loss) before tax (before exceptional items)	204.37	154.12	123.43	358.49	193.97	531.65
3.	Net profit/(loss) before tax (after exceptional items)	204.37	140.94	123.43	345.31	193.97	531.65
4.	Net profit/(loss) after tax	153.87	104.46	89.41	258.33	140.74	390.82
5.	Total comprehensive income/(expense)	154.33	104.92	88.72	259.25	139.35	392.56

- 6 The Consolidated Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on the Company's website www.tatvachintan.com.
- 7 Figures for the previous periods/year have been reclassified/rearranged/regrouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited


Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 19 October 2026



INDEPENDENT AUDITOR'S REVIEW REPORT ON THE STANDALONE STATEMENT OF FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF TATVA CHINTAN PHARMA CHEM LIMITED

1. We have reviewed the accompanying Standalone Statement of Financial Results of Tatva Chintan Pharma Chem Limited ("the Company") for the quarter and half year ended 30th September 2026 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant



CA Basant Chandak

Partner

Membership No.: 434585

UDIN No.: 26434585DBUAOH1630

Date: October 19, 2026

Place: Vadodara



Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Financial Results

for the quarter and half year ended 30 September 2026

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
	Income						
1	Revenue from operations	2,074.84	1,467.02	1,158.63	3,541.86	2,250.43	4,962.96
2	Other income	27.05	40.33	7.94	67.38	21.63	35.28
3	Total income (1+2)	2,101.89	1,507.35	1,166.57	3,609.24	2,272.06	4,998.24
	Expenses						
	Cost of materials consumed	1,140.51	1,054.06	619.87	2,194.57	1,258.76	2,627.49
	Purchases of stock-in-trade	-	-	-	-	-	-
	Changes in inventories of finished goods and work-in-progress	(47.30)	(389.35)	(103.22)	(436.65)	(192.42)	(317.92)
	Employee benefits expense	182.30	167.36	149.47	349.66	290.33	629.32
	Finance costs	27.09	20.81	5.07	47.90	9.20	28.51
	Depreciation and amortisation expense	107.92	105.65	90.53	213.57	180.22	368.42
	Other expenses	487.00	394.70	281.42	881.70	532.00	1,130.77
4	Total expenses	1,897.52	1,353.23	1,043.14	3,250.75	2,078.09	4,466.59
5	Profit before exceptional items and tax (3-4)	204.37	154.12	123.43	358.49	193.97	531.65
6	Exceptional items	-	13.18	-	13.18	-	-
7	Profit before tax (5-6)	204.37	140.94	123.43	345.31	193.97	531.65
	Tax expenses/(benefits)						
	Current tax	17.69	-	21.43	17.69	33.55	100.67
	Deferred tax	32.81	36.48	12.59	69.29	19.68	40.16
8	Total tax expenses	50.50	36.48	34.02	86.98	53.23	140.83
9	Profit for the period/year (7-8)	153.87	104.46	89.41	258.33	140.74	390.82
	Other comprehensive income/(expenses)						
	Items that will not be reclassified to profit or loss	0.62	0.61	(0.98)	1.23	(1.96)	2.45
	Income tax relating to items that will not be reclassified to profit or loss	(0.16)	(0.15)	0.29	(0.31)	0.57	(0.71)
10	Other comprehensive income/(expenses) for the period/year, net of tax	0.46	0.46	(0.69)	0.92	(1.39)	1.74
11	Total comprehensive income for the period/year (9+10)	154.33	104.92	88.72	259.25	139.35	392.56
12	Earnings per share (Face value of Rs 10/- each) (not annualised)						
	- Basic	6.57	4.47	3.82	11.04	6.01	16.71
	- Diluted	6.57	4.47	3.82	11.04	6.01	16.71
13	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92	233.92	233.92
14	Other equity excluding revaluation reserve						7,348.37

Notes forming part of the standalone statement of financial results

1- 6





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Assets and Liabilities

as at 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	31.03.2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	5,589.45	5,741.66
Right-of-use assets	298.35	299.64
Capital work-in-progress	428.27	233.48
Other intangible assets	52.17	52.56
Intangible assets under development	13.29	15.70
Financial assets		
i) Investments	46.67	46.67
ii) Other financial assets	46.12	49.52
Deferred tax assets (net)	7.65	81.68
Other non-current assets	12.00	13.42
Total non-current assets	6,493.97	6,534.33
Current assets		
Inventories	2,244.08	1,694.66
Financial assets		
i) Trade receivables	1,888.71	1,437.19
ii) Cash and cash equivalents	53.48	14.70
iii) Bank balances other than cash and cash equivalents	45.27	30.28
iv) Loans	2.50	2.65
v) Other financial assets	1.44	3.55
Current tax assets (net)	23.00	0.53
Other current assets	223.24	235.93
Total current assets	4,481.72	3,419.49
Total assets	10,975.69	9,953.82
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,560.83	7,348.37
Total equity	7,794.75	7,582.29
Liabilities		
Non-current liabilities		
Financial liabilities		
i) Borrowings	44.65	50.10
Employee benefit obligations	29.80	25.89
Other non-current liabilities	11.06	12.01
Total non-current liabilities	85.51	88.00
Current liabilities		
Financial liabilities		
i) Borrowings	1,655.30	1,153.63
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	196.31	174.77
(b) total outstanding dues of creditors other than above	651.41	398.20
iii) Other financial liabilities	92.81	126.75
Other current liabilities	493.21	421.46
Provisions	6.39	5.55
Current tax liabilities (net)	-	3.17
Total current liabilities	3,095.43	2,283.53
Total equity and liabilities	10,975.69	9,953.82

Notes forming part of the standalone statement of financial results

1- 6





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Cash Flows

for the half year ended 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
A. Cash flows from/(used in) operating activities:			
Profit before tax (i)	345.31	193.97	531.65
Adjustments to reconcile profit:			
Finance costs	47.90	9.20	28.51
Depreciation and amortisation expenses	213.57	180.22	368.42
Unrealised foreign exchange loss/(gain) (net)	(40.25)	4.66	22.65
Interest income	(1.08)	(1.27)	(7.13)
Net gain on sale of current investments	-	(0.06)	(0.06)
Other non-cash items	12.36	0.17	0.53
Total adjustments to reconcile profit (ii)	232.50	192.92	412.92
Operating profit before working capital changes (iii) = (i) + (ii)	577.81	386.89	944.57
Changes in working capital:			
(Increase)/ decrease in inventories	(549.42)	(151.82)	(461.63)
(Increase)/ decrease in trade receivables	(500.00)	(110.75)	(460.89)
(Increase)/ decrease in other non-current financial assets	(0.35)	0.70	(2.95)
(Increase)/ decrease in other current financial assets	57.58	4.27	6.33
(Increase)/ decrease in other non-current assets	1.42	2.09	(2.31)
(Increase)/decrease in other current assets	(15.13)	(142.46)	(33.74)
(Decrease)/increase in trade payables	336.27	42.50	193.74
(Decrease)/increase in other current financial liabilities	(57.95)	(3.59)	(2.72)
(Decrease)/increase in other current liabilities	97.66	128.41	140.39
(Decrease)/increase in non-current provisions	3.90	-	11.90
(Decrease)/increase in current provisions	0.84	0.42	1.31
Total changes in working capital (iv)	(625.18)	(230.23)	(610.57)
Cash generated from/ (used in) operating activities (v) = (iii) + (iv)	(47.37)	156.66	334.00
Less: Taxes paid (net of refund)	(38.33)	(36.54)	(42.35)
Net cash generated from/ (used in) operating activities (A) = (v) + (vi)	(85.70)	120.12	291.65
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)	(308.45)	(559.99)	(1,137.65)
Government grant received for capital asset	-	-	14.20
Proceeds from sale of property, plant and equipment	2.76	0.03	3.58
(Increase)/decrease in deposits with banks	(11.23)	(19.13)	(6.80)
Purchase of Investment (Non current)	-	-	(40.00)
Purchase of Investment (Current)	-	(40.01)	(40.00)
Proceeds from sale of current investments	-	40.07	40.06
Interest income	3.55	1.27	8.28
Cash (used in) investing activities (B)	(313.37)	(577.76)	(1,158.33)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Cash Flows

for the half year ended 30 September 2026

(Currency: Indian Rupees in million)

Particulars	30.09.2026 (Unaudited)	30.09.2025 (Unaudited)	31.03.2026 (Audited)
C. Cash flows from financing activities:			
Dividend paid	(8.55)	-	(23.39)
Proceeds from Non-current borrowings	-	-	60.40
Repayment of long-term borrowings	(5.06)	(4.43)	(6.38)
Net proceeds from short-term borrowings	501.27	470.68	785.84
Decrease / (increase) in loans to employees	0.15	0.27	(0.28)
Interest paid	(49.95)	(9.20)	(26.87)
Cash generated from financing activities (C)	437.86	457.32	789.32
Net decrease in cash and cash equivalents D=(A+B+C)	38.79	(0.32)	(77.36)
Cash and cash equivalents at the beginning of the year (E)	14.70	92.05	92.05
Effect of exchange rate changes on cash and cash equivalents (F)	(0.01)	-	0.01
Cash and cash equivalents at the end of the year (D+E+F)	53.48	91.73	14.70
Components of cash and cash equivalents:			
Cash on hand	0.83	0.87	0.82
Balances with banks:			
- in current accounts	0.44	0.64	7.34
- in cash credit accounts (surplus)	-	-	0.01
- in EEFC current accounts	43.76	85.40	1.61
- in deposits with original maturity of less than 3 months	8.45	4.82	4.92
Balance as per statement of cash flows	53.48	91.73	14.70

Notes forming part of the standalone statement of financial results

1- 6





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Standalone Statement of Financial Results

for the quarter and half year ended 30 September 2026

(Currency: Indian Rupees in million)

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Standalone Financial Results for the quarter and half year ended 30 September 2026 ("Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 19 October 2026.
- 2 The Standalone Financial Results of the Company for the quarter and half year ended 30 September 2026, have been subjected to limited review by the statutory auditors of the Company, who have expressed an unmodified opinion.
- 3 The Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- 5 The Standalone Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on the Company's website www.tatvachintan.com.
- 6 Figures for the previous periods/year have been reclassified/rearranged/regrouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited

Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 19 October 2026

